Tubulointerstitial Injury Associated With Chemotherapeutic Agents

Slides:



Advertisements
Similar presentations
Volume 62, Issue 6, Pages (December 2002)
Advertisements

Long-term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury  Yan Xie, Benjamin Bowe, Tingting Li, Hong Xian,
Presented By Dr / Said Said Elshama
Kidney Involvement in Leukemia and Lymphoma
Lakhmir S. Chawla, Paul L. Kimmel  Kidney International 
Chronic Pain in End-Stage Renal Disease
AJKD Atlas of Renal Pathology: Ischemic Acute Tubular Injury
Renal Tubular Acidosis and the Nephrology Teaching Paradigm
Sheldon Chen  Advances in Chronic Kidney Disease 
Long-term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury  Yan Xie, Benjamin Bowe, Tingting Li, Hong Xian,
Diagnosis and Management of Chronic Kidney Disease
Changing Terminology in Renal Research: The Impact of Consensus
Corey Cavanaugh, Mark A. Perazella  American Journal of Kidney Diseases 
Blaithin A. McMahon, Patrick Thomas Murray  Kidney International 
MyPlate for Healthy Eating With Chronic Kidney Disease (MyPlate Education for Patients With Chronic Kidney Disease Receiving Hemodialysis and Peritoneal.
A Decade After the KDOQI CKD Guidelines
Update on acute kidney injury after cardiac surgery
Kidney Involvement in Leukemia and Lymphoma
Volume 67, Issue 5, Pages (May 2005)
Management of Acute Kidney Injury: Core Curriculum 2018
Toxic Nephropathies: Core Curriculum 2010
Why Do Patients Develop Proteinuria With Sirolimus
An Update on Neurocritical Care for the Patient With Kidney Disease
John P. Middleton, Patrick H. Pun  Kidney International 
Improving Carboplatin Dosing Based on Estimated GFR
Peter A. McCullough, MD, MPH  Advances in Chronic Kidney Disease 
Chronic Pain in End-Stage Renal Disease
Kidney specific factors that enhance nephrotoxic risk are noted.
Autosomal dominant distal renal tubular acidosis and the AE1 gene
AJKD Atlas of Renal Pathology: Indinavir Nephrotoxicity
Volume 79, Issue 1, Pages (January 2011)
Pharmacology behind Common Drug Nephrotoxicities Perazella, Mark A
The ESRD Uninsured Matter
Set Theory: Nephrology ∩ Urology
Dinna N. Cruz  Advances in Chronic Kidney Disease 
CKD as an Underrecognized Threat to Patient Safety
Figure 3 Pathophysiological events and preventive
Eric J. Seeley  Advances in Chronic Kidney Disease 
AJKD Atlas of Renal Pathology: Toxic Acute Tubular Injury
Volume 72, Issue 2, Pages (July 2007)
The Kidney Effects of Hematopoietic Stem Cell Transplantation
Drug Dose Adjustments in Patients With Renal Impairment
A Fundamental Theorem of Telehealth
Dennis G. Moledina, MD, Mark A. Perazella, MD 
Daniel L. Landry, DO, FASN  Advances in Chronic Kidney Disease 
Crossing Vessel and Crossroads With Urology
Current Concepts in Hemodialysis Vascular Access Infections
Long-term Outcomes of Acute Kidney Injury: The Power and Pitfalls of Observational/Population-Based Studies  Charuhas V. Thakar, MD  American Journal.
New drug toxicities in the onco-nephrology world
Improving Carboplatin Dosing Based on Estimated GFR
Perioperative Acute Kidney Injury
Advances in the pathogenesis of HIV-associated kidney diseases
NODding off in acute kidney injury with progranulin?
Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies
Volume 80, Issue 10, Pages (November 2011)
Anil K. Saxena, MD, B.R. Panhotra, MD, PhD, MNAMS 
Internet Organ Solicitation, Explained
Patient Safety Issues in CKD: Core Curriculum 2015
Pharmacology American Journal of Kidney Diseases
Nocturia and Aging: Diagnosis and Treatment
Adiponectin: good, bad, or just plain ugly?
Tumor necrosis factor-α in cisplatin nephrotoxicity: A homebred foe?
Basolateral transport of drugs.
Emergence of the Concept of Acute Kidney Injury
Patient factors that increase risk for drug-induced nephrotoxicity.
Bisphosphonate nephrotoxicity
Decision-Making in Patients With Cancer and Kidney Disease
Kidney factors that enhance risk for drug-induced nephrotoxicity.
Cisplatin (Cis) nephrotoxicity is, in part, related to its uptake by proximal tubular cells. Cisplatin (Cis) nephrotoxicity is, in part, related to its.
AJKD Atlas of Renal Pathology: Ischemic Acute Tubular Injury
Presentation transcript:

Tubulointerstitial Injury Associated With Chemotherapeutic Agents Anushree C. Shirali, Mark A. Perazella  Advances in Chronic Kidney Disease  Volume 21, Issue 1, Pages 56-63 (January 2014) DOI: 10.1053/j.ackd.2013.06.010 Copyright © 2014 National Kidney Foundation, Inc. Terms and Conditions

Figure 1 Cisplatin-associated nephrotoxicity. Cisplatin causes kidney injury via multiple mechanisms. Uptake into proximal tubular cells is associated with toxicity via cell signaling pathways, inflammation, and increased oxidative stress. Vascular injury also causes tubular ischemia and acute kidney injury. OCT-2, organic cation transporter-2; RTEC, renal tubular epithelial cell; TNF-α, tumor necrosis factor-α. Advances in Chronic Kidney Disease 2014 21, 56-63DOI: (10.1053/j.ackd.2013.06.010) Copyright © 2014 National Kidney Foundation, Inc. Terms and Conditions

Figure 2 Ifosfamide-associated nephrotoxicity. Unlike cyclophosphamide, methotrexate is transported into proximal tubular cells via the OCT-2 on the basolateral membrane and is metabolized to the tubular toxic substance chloracetaldehyde. AKI, acute kidney injury; ATN, acute tubular necrosis; OCT, organic cation transporter-2. Advances in Chronic Kidney Disease 2014 21, 56-63DOI: (10.1053/j.ackd.2013.06.010) Copyright © 2014 National Kidney Foundation, Inc. Terms and Conditions

Figure 3 Prevention and treatment of methotrexate nephrotoxicity. High-risk patients more commonly develop nephrotoxicity from high-dose methotrexate. Preventive strategies include intravenous fluids, urinary alkalinization, and leucovorin rescue. When acute kidney injury develops and drug levels are excessive, glucarbidase and high-flux hemodialysis should be considered. HD, hemodialysis; IV, intravenous; GFR, glomerular filtration rate. Advances in Chronic Kidney Disease 2014 21, 56-63DOI: (10.1053/j.ackd.2013.06.010) Copyright © 2014 National Kidney Foundation, Inc. Terms and Conditions